Citadel Advisors
GMAB icon

Citadel Advisors’s Genmab GMAB Stock Holding History

Citadel Advisors’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.58M Buy
312,300
+139,800
+81% +$3.72M ﹤0.01% 3813
2026
Q1 		$4.63M Buy
172,500
+145,600
+541% +$4.36M ﹤0.01% 4468
2025
Q4 		$829K Sell
26,900
-3,100
-10% -$96.6K ﹤0.01% 7833
2025
Q3 		$920K Buy
30,000
+11,700
+64% +$285K ﹤0.01% 7710
2025
Q2 		$378K Sell
18,300
-29,900
-62% -$614K ﹤0.01% 9280
2025
Q1 		$944K Buy
48,200
+32,500
+207% +$682K ﹤0.01% 7083
2024
Q4 		$328K Buy
15,700
+5,500
+54% +$121K ﹤0.01% 9474
2024
Q3 		$249K Buy
10,200
+3,400
+50% +$90.9K ﹤0.01% 9687
2024
Q2 		$171K Sell
6,800
-6,600
-49% -$187K ﹤0.01% 10156
2024
Q1 		$401K Buy
13,400
+1,700
+15% +$49.9K ﹤0.01% 8859
2023
Q4 		$373K Buy
11,700
+1,100
+10% +$34.5K ﹤0.01% 8706
2023
Q3 		$374K Buy
10,600
+6,000
+130% +$229K ﹤0.01% 8693
2023
Q2 		$175K Sell
4,600
-29,700
-87% -$1.18M ﹤0.01% 10091
2023
Q1 		$1.3M Buy
34,300
+31,300
+1,043% +$1.2M ﹤0.01% 6245
2022
Q4 		$127K Sell
3,000
-170,100
-98% -$7.01M ﹤0.01% 10857
2022
Q3 		$5.56M Buy
173,100
+91,600
+112% +$3.22M ﹤0.01% 3696
2022
Q2 		$2.65M Buy
81,500
+58,100
+248% +$1.88M ﹤0.01% 4992
2022
Q1 		$847K Buy
23,400
+16,800
+255% +$577K ﹤0.01% 8089
2021
Q4 		$261K Buy
6,600
+800
+14% +$33.4K ﹤0.01% 11241
2021
Q3 		$253K Sell
5,800
-5,000
-46% -$224K ﹤0.01% 11449
2021
Q2 		$441K Sell
10,800
-53,100
-83% -$2.05M ﹤0.01% 10333
2021
Q1 		$2.1M Buy
63,900
+40,600
+174% +$1.53M ﹤0.01% 6271
2020
Q4 		$947K Buy
23,300
+1,300
+6% +$48.6K ﹤0.01% 6906
2020
Q3 		$805K Buy
22,000
+3,900
+22% +$141K ﹤0.01% 6410
2020
Q2 		$613K Buy
+18,100
New +$493K ﹤0.01% 6706

Other funds holding GMAB

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Citadel Advisors's GMAB Position: Q2 2026 in Review

Citadel Advisors opened a new position in Genmab (GMAB) in Q2 2026: 2,475,991 shares worth $68M. The stake represents 0.01% of the portfolio and ranks #1268 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in GMAB as recently as Q4 2025.

Citadel Advisors first reported a position in GMAB in Q3 2019 and has held it in 25 quarters since. The position peaked at $86.7M in Q1 2025. 292 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • Citadel Advisors held 2,475,991 shares of Genmab worth $68M as of Q2 2026.
  • Genmab was a new Citadel Advisors position in Q2 2026.
  • Genmab made up 0.01% of Citadel Advisors's portfolio in Q2 2026, its #1268 holding.
  • Citadel Advisors first reported a position in Genmab in Q3 2019 and has held it in 25 quarters since.
  • Citadel Advisors's Genmab position peaked at $86.7M in Q1 2025.
  • 292 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.